Table 2.
Comorbidities of patients undergoing TAVR through transapical vs. nontransapical approaches.
| Non-TA-TAVR | TA-TAVR | p value | |
|---|---|---|---|
| Hypertension | 52.19 | 74.15 | 0.0001 |
| Type 2 DM | 37.38 | 34.57 | 0.0109 |
| Chronic ischemic heart disease | 40.23 | 62.39 | 0.0001 |
| Acute myocardial infarction | 1.82 | 1.79 | 0.92 |
| Dyslipidemia | 67.48 | 66.4 | 0.37 |
| Peripheral vascular disease | 20.03 | 35.32 | 0.0001 |
| Obesity | 14.57 | 11.19 | 0.0001 |
| Chronic kidney disease | 35.16 | 33.13 | 0.12 |
| ESRD | 3.56 | 3.88 | 0.48 |
| Atrial fibrillation | 31.59 | 44.62 | 0.0001 |
| Chronic liver disease | 1.53 | 1.24 | 0.32 |
| Chronic lung disease | 32.87 | 42.79 | 0.0001 |
| Smoking status | 34.77 | 33.52 | 0.31 |
| Alcohol consumption | 0.75 | 0.5 | 0.19 |